<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894919</url>
  </required_header>
  <id_info>
    <org_study_id>V72_28E1</org_study_id>
    <secondary_id>2012-000657-30</secondary_id>
    <nct_id>NCT01894919</nct_id>
  </id_info>
  <brief_title>Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28</brief_title>
  <official_title>A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this extension study is to explore the antibody persistence 24 to 36 months after
      the last dose of vaccine, in infants that received a two or three dose primary series plus a
      booster dose at 11 months of age, of the Novartis meningococcal B vaccine (Bexsero®) in
      groups I to III of the parent V72_28 study.

      This study will also explore the antibody persistence 24 to 36 months after two catch-up
      doses of the Novartis meningococcal B vaccine (Bexsero®) administered in children (2 to 10
      years old) in group IV of the parent V72_28 study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains</measure>
    <time_frame>24 or 36 months after booster dose in the parent study; baseline for vaccine-naïve subjects</time_frame>
    <description>The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules, is presented in terms of the percentage of subjects in each vaccine group, with hSBA titers ≥ 4 for what concerns the H44/76, 5/99 and NZ98/254 strains, and hSBA titers ≥ 5 for M10713 strain, alongside with the corresponding antibody responses in age-matched vaccine naïve subjects at baseline.
The functional bactericidal antibodies directed against serogroup B meningococcal were assessed by the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis Serogroup B Strains</measure>
    <time_frame>At 24-36 months after booster dose in the parent study: baseline for vaccine-naïve subjects</time_frame>
    <description>The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules is presented in terms of the percentage of subjects in each vaccine group with hSBA titers ≥ 8, alongside with the corresponding antibody responses in age matched vaccine naïve subjects at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains</measure>
    <time_frame>24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects</time_frame>
    <description>The hSBA antibody titers in subjects, 24 to 36 months after completion of Bexsero® vaccination course according to different schedules in the parent study, are presented in terms of vaccine-group-specific GMTs, alongside with the corresponding antibody responses in age-matched vaccine-naïve subjects at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus 1 Month After Completion of Bexsero® Vaccination Course According to Different Schedules in the Parent Study.</measure>
    <time_frame>At Day 1 in this study over one month after the completion of the vaccination course in the parent study</time_frame>
    <description>The within-subjects GMR of GMTs at 24 to 36 months versus 1 month after completion of Bexsero® vaccination course according to different schedules vaccination in parent study are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus Visit 1 in the Parent Study.</measure>
    <time_frame>At Day 1 in this study over visit 1 in the vaccination course in the parent study</time_frame>
    <description>The within-subjects GMR of GMTs at 24 to 36 months versus visit 1 in the vaccination course according to different schedules vaccination in the parent study are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titers ≥4 or ≥ 5 Against N.Meningitidis Serogroup B, After Receiving Bexsero® Booster Vaccination in This Study.</measure>
    <time_frame>At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)</time_frame>
    <description>The percentage of subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and with hSBA titers ≥ 5 against M10713 strain, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study), alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis serogroupB, After Receiving Bexsero® Booster Vaccination in This Study.</measure>
    <time_frame>At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)</time_frame>
    <description>The percentage of subjects with hSBA titers ≥ 8, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Bexsero® Vaccination in This Study.</measure>
    <time_frame>One month after booster vaccination (day 31)/24-36 months (Visit 1)</time_frame>
    <description>The percentage of subjects with a four-fold rise in hSBA titers after receiving Bexsero® booster vaccination in this study to pre vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.</measure>
    <time_frame>At Visit 1 and one month post booster vaccination (Day 31)</time_frame>
    <description>The hSBA antibody titers in subjects after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the 1st dose of Bexsero® vaccine in age matched vaccine-naïve subjects in terms of GMTs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.</measure>
    <time_frame>Day 1 and Day 31</time_frame>
    <description>The within-subjects GMR of hSBA antibody titers (one month post booster vaccination versus pre vaccination) after Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the within-subject GMR for the 1st dose of rMenB+OMV NZ vaccination of age matched naïve subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titers ≥ 4 or ≥ 5, After Receiving Two Catch up Doses of Bexsero® Vaccination</measure>
    <time_frame>At Baseline and One month post second vaccination (Day 61)</time_frame>
    <description>The percentage of vaccine-naïve subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and ≥ 5 against M10713 strain, one month after receiving two catch up doses of Bexsero® booster vaccination in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titers ≥ 8 , After Receiving Two Catch up Doses of Bexsero® Vaccination.</measure>
    <time_frame>At Baseline and One month post second vaccination (Day 61)</time_frame>
    <description>The percentage of vaccine-naïve subjects with hSBA titers ≥8, one month after receiving two catch up doses of Bexsero® booster vaccination in this study are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Two Catch up Doses of Bexsero® Vaccination.</measure>
    <time_frame>One month post second vaccination (Day 61)</time_frame>
    <description>The percentage of vaccine-naïve subjects with a four-fold rise in hSBA titers from baseline, one month after receiving two catch up doses of Bexsero® booster vaccination in comparison to prevaccination in this study are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The GMTs in Subjects Who Received Two Catch up Doses of Bexsero® Vaccination.</measure>
    <time_frame>At Baseline and One month post second vaccination (Day 61)</time_frame>
    <description>The hSBA antibody titers in vaccine-naïve subjects , after receiving two catch up doses of Bexsero® vaccination in this study, are reported in terms of GMTs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The GMRs of hSBA Titers After Two Catch up Doses of Bexsero® Vaccination Versus hSBA Titers at Baseline.</measure>
    <time_frame>At Baseline (Day 1)</time_frame>
    <description>The within-subject GMRs of hSBA titers at one month after receiving the second catch up dose to hSBA titers at baseline, for naïve subjects who received two catch up doses of Bexsero® vaccination in this study are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (35 Months to 7 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.</measure>
    <time_frame>From day 1 (6 hr) through day 7 after vaccination</time_frame>
    <description>The number of subjects (35 months to 7 years of age) with solicited local and systemic adverse events after receivingBexsero® booster vaccine in the present study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Newly Recruited Subjects (Aged 35 Months to 7 Years) Reporting Solicited Local and Systemic Adverse Events After Receiving Catch-up Doses of Bexsero® Vaccine.</measure>
    <time_frame>The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study</time_frame>
    <description>The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (8 to 12 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.</measure>
    <time_frame>From day 1 (6 hr) through day 7 after vaccination</time_frame>
    <description>Number of subjects (8 to 12 years of age) reporting solicited local and systemic adverse events after receiving Bexsero® booster vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Newly Recruited naïve Subjects (Aged 8 to 12 Years of Age) Solicited Local and Systemic Adverse Events After Receiving Bexsero® Vaccine.</measure>
    <time_frame>From day 1(6 hr) through day 7 after vaccination</time_frame>
    <description>The number newly recruited naïve subjects (aged 8 to12 years of age) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination.</measure>
    <time_frame>From day 1 through day 7 after any vaccination and throughout entire study period for all other AEs.</time_frame>
    <description>The number of subjects reporting unsolicited adverse events after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) or two cach up schedule of Bexsero® vaccine is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs), Medically Attended AEs and AEs Leading to Withdrawal for Entire Study Period.</measure>
    <time_frame>Throughout the entire study period</time_frame>
    <description>The number of subjects reporting unsolicited SAEs, medically attended AEs and AEs leading to withdrawal after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in the parent study) or two catch-up schedule of Bexsero® vaccine is reported.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">851</enrollment>
  <condition>Meningoccocal Disease</condition>
  <condition>Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>2H3H511_V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2H3H511_NV</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3H5_11_V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3H5_11_NV</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68_11_V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68_11_NV</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>02_2_5_V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>02_2_5_NV</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>02_6_10_V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>02_6_10_NV</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAIVE 123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAIVE_4A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAIVE_4B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bexsero® vaccine (1 dose at study month zero)</intervention_name>
    <arm_group_label>02_2_5_V</arm_group_label>
    <arm_group_label>02_6_10_V</arm_group_label>
    <arm_group_label>2H3H511_V</arm_group_label>
    <arm_group_label>3H5_11_V</arm_group_label>
    <arm_group_label>68_11_V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bexsero® vaccine (2 doses 1 month apart)</intervention_name>
    <arm_group_label>NAIVE 123</arm_group_label>
    <arm_group_label>NAIVE_4A</arm_group_label>
    <arm_group_label>NAIVE_4B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For naïve subjects newly enrolled:

          1. Healthy infants and children according to the following age groups:

               1. Healthy subjects from 35 to 47 months of age, (only applicable to group K) (The
                  age window is defined as the first day the subject turns 35 months of age up to
                  the day before the subject turns 48 months of age),

               2. Healthy subjects 4 to 7 years of age (only applicable to group L) (The age window
                  is defined as the first day the subject turns 4 years of age up to the day before
                  the subject turns 8 years of age).

               3. Healthy subjects 8 to 12 years of age (only applicable to group M) (The age
                  window is defined as the first day the subject turns 8 years of age up to the day
                  before the subject turns 13 years of age).

          2. for whom a parent/legal guardian has given written informed consent after the nature
             of the study has been explained;

          3. for whom a parent/legal guardian confirmed availability for the visit scheduled in the
             study;

          4. in good health as determined by medical history, physical examination, clinical
             judgment of the investigator.

        For Subjects who participated in the V72_28 study (Follow-on Subjects):

          1. for whom a parent/legal guardian has given written informed consent after the nature
             of the study has been explained;

          2. for whom a parent/legal guardian confirmed availability for the visit scheduled in the
             study;

          3. in good health as determined by medical history, physical examination, clinical
             judgment of the investigator

          4. who have completed the vaccination course in the V72_28 study and have received their
             last vaccination 24 to 36 months before enrollment in V72_28E1

        Exclusion Criteria:

        For naïve subjects newly enrolled:

          1. History of any serogroup B meningococcal vaccine administration;

          2. Previous known or suspected disease caused by N. meningitidis;

          3. Household contact with and/or intimate exposure to an individual with laboratory
             confirmed N. meningitidis infection or colonization;

          4. History of severe allergic reaction after previous vaccinations or hypersensitivity to
             any component of the vaccine;

          5. Pregnancy or nursing (breastfeeding) mothers;

          6. Females of childbearing age who have not used or do not plan to use acceptable birth
             control measures, for the duration of the study. Oral, injected or implanted hormonal
             contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine
             device, surgical sterilization, transdermal delivery, congenital sterility or sexual
             abstinence are considered acceptable forms of birth control. If sexually active the
             subject must have been using one of the accepted birth control methods at least two
             months prior to study entry;

          7. Known or suspected autoimmune disease or impairment/alteration of the immune system
             resulting from (for example):

               -  Receipt of any chronic immunosuppressive therapy

               -  Receipt of any chronic immunostimulants

               -  Immune deficiency disorder, or known HIV infection

          8. History of seizure, any progressive neurological disease or Guillain Barré Syndrome
             (exception: one self-limited febrile seizure is acceptable).

          9. Known bleeding diathesis or any condition that may be associated with a prolonged
             bleeding time.

         10. Subject's parent(s) or legal guardian(s) are not able to comprehend and to follow all
             required study procedures for the whole period of the study.

         11. Intent to participate in another clinical study during this study.

         12. Family members and household members of study staff;

         13. History or any illness/condition which, in the opinion of the investigator, might
             interfere with the evaluation of the study objectives or pose additional risk to the
             subjects due to participation in the study.

         14. Any significant chronic infection.

         15. Any serious chronic or progressive disease according to judgment of the investigator
             (e.g. neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).

        For Subjects who participated in the V72_28 study (Follow-on Subjects):

        Exclusion criteria are the same as for naïve subjects, with the exception of criterion 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 34, General Pediatric Practice Somorjai</name>
      <address>
        <city>Debrecen</city>
        <state>Bajcsi Ut 32</state>
        <zip>4025</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35, Praxis Dr Eva Kovacs</name>
      <address>
        <city>Szeged</city>
        <state>Csongradi Sgt 63</state>
        <zip>6723</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36, General Practice Dr Edit Oszlacs</name>
      <address>
        <city>Szeged</city>
        <state>Debreceni Utca 10-14</state>
        <zip>6723</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 37, Praxis Dr Julianna Kovacs</name>
      <address>
        <city>Bordany</city>
        <state>Honved Utca 2</state>
        <zip>6795</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31, General Practice Dr Olga Fekete</name>
      <address>
        <city>Miskolc</city>
        <state>Kando Kalman Utca 1</state>
        <zip>3534</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 40, General Pediatric Practice Hacsek</name>
      <address>
        <city>Budapest</city>
        <state>Poth Iren U 80</state>
        <zip>1188</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30, General Practice Dr Simko</name>
      <address>
        <city>Miskolc</city>
        <state>Selyemret U. 1.</state>
        <zip>3527</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33, General Pediatric Practice Ujhelyi</name>
      <address>
        <city>Nyiregyhaza</city>
        <state>Szent Istvan U 10</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42, Praxis Dr Eszter Bari</name>
      <address>
        <city>Csongrad</city>
        <state>Szentharomsag Ter 10</state>
        <zip>6640</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Almeria</city>
        <zip>04007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Almeria</city>
        <zip>04120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20</name>
      <address>
        <city>Barcelona</city>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>Madrid</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <results_first_submitted>November 15, 2016</results_first_submitted>
  <results_first_submitted_qc>May 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 7, 2018</results_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal B disease,</keyword>
  <keyword>Antibody persistence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 9 study sites in Hungary and 8 study sites in Spain.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2H3H511_V</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="P2">
          <title>2H3H511_NV</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="P3">
          <title>3H5_11_V</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="P4">
          <title>3H5_11_NV</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="P5">
          <title>68_11_V</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="P6">
          <title>68_11_NV</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="P7">
          <title>02_2_5_V</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="P8">
          <title>02_2_5_NV</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="P9">
          <title>02_6_10_V</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="P10">
          <title>02_6_10_NV</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catchup doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="P11">
          <title>NAIVE 123</title>
          <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
        </group>
        <group group_id="P12">
          <title>NAIVE_4A</title>
          <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
        </group>
        <group group_id="P13">
          <title>NAIVE_4B</title>
          <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="89"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="81"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="36"/>
                <participants group_id="P9" count="91"/>
                <participants group_id="P10" count="90"/>
                <participants group_id="P11" count="100"/>
                <participants group_id="P12" count="55"/>
                <participants group_id="P13" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="89"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="78"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="36"/>
                <participants group_id="P9" count="91"/>
                <participants group_id="P10" count="89"/>
                <participants group_id="P11" count="98"/>
                <participants group_id="P12" count="55"/>
                <participants group_id="P13" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other-Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2H3H511_V</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="B2">
          <title>2H3H511_NV</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="B3">
          <title>3H5_11_V</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="B4">
          <title>3H5_11_NV</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="B5">
          <title>68_11_V</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="B6">
          <title>68_11_NV</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="B7">
          <title>02_2_5_V</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="B8">
          <title>02_2_5_NV</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="B9">
          <title>02_6_10_V</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="B10">
          <title>02_6_10_NV</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catchup doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.</description>
        </group>
        <group group_id="B11">
          <title>NAIVE 123</title>
          <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
        </group>
        <group group_id="B12">
          <title>NAIVE_4A</title>
          <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
        </group>
        <group group_id="B13">
          <title>NAIVE_4B</title>
          <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="89"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="81"/>
            <count group_id="B6" value="39"/>
            <count group_id="B7" value="32"/>
            <count group_id="B8" value="36"/>
            <count group_id="B9" value="91"/>
            <count group_id="B10" value="90"/>
            <count group_id="B11" value="100"/>
            <count group_id="B12" value="55"/>
            <count group_id="B13" value="50"/>
            <count group_id="B14" value="851"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="0.2"/>
                    <measurement group_id="B2" value="3" spread="0.18"/>
                    <measurement group_id="B3" value="3.1" spread="0.23"/>
                    <measurement group_id="B4" value="3.1" spread="0.22"/>
                    <measurement group_id="B5" value="3.2" spread="0.29"/>
                    <measurement group_id="B6" value="3.2" spread="0.26"/>
                    <measurement group_id="B7" value="6.5" spread="1.15"/>
                    <measurement group_id="B8" value="6.7" spread="1.16"/>
                    <measurement group_id="B9" value="10.4" spread="1.43"/>
                    <measurement group_id="B10" value="10.4" spread="1.44"/>
                    <measurement group_id="B11" value="3.4" spread="0.29"/>
                    <measurement group_id="B12" value="5.8" spread="1.12"/>
                    <measurement group_id="B13" value="9.7" spread="1.38"/>
                    <measurement group_id="B14" value="5.6" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="44"/>
                    <measurement group_id="B10" value="46"/>
                    <measurement group_id="B11" value="46"/>
                    <measurement group_id="B12" value="26"/>
                    <measurement group_id="B13" value="27"/>
                    <measurement group_id="B14" value="422"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="21"/>
                    <measurement group_id="B9" value="47"/>
                    <measurement group_id="B10" value="44"/>
                    <measurement group_id="B11" value="54"/>
                    <measurement group_id="B12" value="29"/>
                    <measurement group_id="B13" value="23"/>
                    <measurement group_id="B14" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains</title>
        <description>The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules, is presented in terms of the percentage of subjects in each vaccine group, with hSBA titers ≥ 4 for what concerns the H44/76, 5/99 and NZ98/254 strains, and hSBA titers ≥ 5 for M10713 strain, alongside with the corresponding antibody responses in age-matched vaccine naïve subjects at baseline.
The functional bactericidal antibodies directed against serogroup B meningococcal were assessed by the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA).</description>
        <time_frame>24 or 36 months after booster dose in the parent study; baseline for vaccine-naïve subjects</time_frame>
        <population>Analysis was done on Full Analysis Set (FAS)-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511</title>
            <description>Combined group 4D_2-11M/B + group 4D_2-11M - Subjects who received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O2">
            <title>3H5_11</title>
            <description>Combined group 3D_3-11M/B + group 3D_3-11M - Subjects who received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O3">
            <title>68_11</title>
            <description>Combined group 3D_6-11Y/B + group 3D_6-11M - Subjects who received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O4">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O5">
            <title>02_2_5</title>
            <description>Combined group 2D_2-5Y/B + group 2D_2-5Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 2 and 5 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O6">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O7">
            <title>02_6_10</title>
            <description>Combined group 2D_6-10Y/B + group 2D_6-10Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 6 and 10 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study V72_28 (NCT01894919).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains</title>
          <description>The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules, is presented in terms of the percentage of subjects in each vaccine group, with hSBA titers ≥ 4 for what concerns the H44/76, 5/99 and NZ98/254 strains, and hSBA titers ≥ 5 for M10713 strain, alongside with the corresponding antibody responses in age-matched vaccine naïve subjects at baseline.
The functional bactericidal antibodies directed against serogroup B meningococcal were assessed by the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA).</description>
          <population>Analysis was done on Full Analysis Set (FAS)-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="179"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (N=140;131;119;100;67;55;178;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="42.8" upper_limit="60"/>
                    <measurement group_id="O2" value="53" lower_limit="43.8" upper_limit="61.5"/>
                    <measurement group_id="O3" value="61" lower_limit="52" upper_limit="70.1"/>
                    <measurement group_id="O4" value="38" lower_limit="28.5" upper_limit="48.3"/>
                    <measurement group_id="O5" value="52" lower_limit="39.7" upper_limit="64.6"/>
                    <measurement group_id="O6" value="27" lower_limit="16.1" upper_limit="41"/>
                    <measurement group_id="O7" value="58" lower_limit="50.3" upper_limit="65.2"/>
                    <measurement group_id="O8" value="20" lower_limit="10" upper_limit="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N=140;131;119;100;67;55;179;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="77.2" upper_limit="89.9"/>
                    <measurement group_id="O2" value="88" lower_limit="80.9" upper_limit="92.9"/>
                    <measurement group_id="O3" value="93" lower_limit="87.2" upper_limit="97.1"/>
                    <measurement group_id="O4" value="3" lower_limit="0.6" upper_limit="8.5"/>
                    <measurement group_id="O5" value="79" lower_limit="67.4" upper_limit="88.1"/>
                    <measurement group_id="O6" value="4" lower_limit="0.44" upper_limit="12.5"/>
                    <measurement group_id="O7" value="85" lower_limit="79.4" upper_limit="90.3"/>
                    <measurement group_id="O8" value="8" lower_limit="2.2" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=140;131;119;100;67;55;179;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="36.6" upper_limit="53.6"/>
                    <measurement group_id="O2" value="38" lower_limit="29.8" upper_limit="47.1"/>
                    <measurement group_id="O3" value="56" lower_limit="46.9" upper_limit="65.4"/>
                    <measurement group_id="O4" value="2" lower_limit="0.24" upper_limit="7"/>
                    <measurement group_id="O5" value="29" lower_limit="19" upper_limit="41.7"/>
                    <measurement group_id="O6" value="7" lower_limit="2" upper_limit="17.6"/>
                    <measurement group_id="O7" value="50" lower_limit="42.2" upper_limit="57.3"/>
                    <measurement group_id="O8" value="6" lower_limit="1.3" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N=127;111;109;93;65;53;173;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="22.8" upper_limit="39.5"/>
                    <measurement group_id="O2" value="36" lower_limit="27.1" upper_limit="45.7"/>
                    <measurement group_id="O3" value="39" lower_limit="29.4" upper_limit="48.3"/>
                    <measurement group_id="O4" value="37" lower_limit="26.8" upper_limit="47.2"/>
                    <measurement group_id="O5" value="34" lower_limit="22.6" upper_limit="46.6"/>
                    <measurement group_id="O6" value="38" lower_limit="24.8" upper_limit="52.1"/>
                    <measurement group_id="O7" value="61" lower_limit="53.0" upper_limit="68.0"/>
                    <measurement group_id="O8" value="55" lower_limit="40.2" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis Serogroup B Strains</title>
        <description>The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules is presented in terms of the percentage of subjects in each vaccine group with hSBA titers ≥ 8, alongside with the corresponding antibody responses in age matched vaccine naïve subjects at baseline.</description>
        <time_frame>At 24-36 months after booster dose in the parent study: baseline for vaccine-naïve subjects</time_frame>
        <population>Analysis was done on FAS-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511</title>
            <description>Combined group 4D_2-11M/B + group 4D_2-11M - Subjects who received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O2">
            <title>3H5_11</title>
            <description>Combined group 3D_3-11M/B + group 3D_3-11M - Subjects who received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O3">
            <title>68_11</title>
            <description>Combined group 3D_6-11Y/B + group 3D_6-11M - Subjects who received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O4">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O5">
            <title>02_2_5</title>
            <description>Combined group 2D_2-5Y/B + group 2D_2-5Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 2 and 5 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O6">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O7">
            <title>02_6_10</title>
            <description>Combined group 2D_6-10Y/B + group 2D_6-10Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 6 and 10 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study V72_28 (NCT01894919).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis Serogroup B Strains</title>
          <description>The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules is presented in terms of the percentage of subjects in each vaccine group with hSBA titers ≥ 8, alongside with the corresponding antibody responses in age matched vaccine naïve subjects at baseline.</description>
          <population>Analysis was done on FAS-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="179"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (N=140;131;119;100;67;55;178;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="20.6" upper_limit="36.1"/>
                    <measurement group_id="O2" value="26" lower_limit="18.7" upper_limit="34.3"/>
                    <measurement group_id="O3" value="32" lower_limit="23.7" upper_limit="41.1"/>
                    <measurement group_id="O4" value="18" lower_limit="11" upper_limit="26.9"/>
                    <measurement group_id="O5" value="24" lower_limit="14.3" upper_limit="35.9"/>
                    <measurement group_id="O6" value="16" lower_limit="7.8" upper_limit="28.8"/>
                    <measurement group_id="O7" value="34" lower_limit="26.8" upper_limit="41.2"/>
                    <measurement group_id="O8" value="10" lower_limit="3.3" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N=140;131;119;100;67;55;179;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="72.4" upper_limit="86.3"/>
                    <measurement group_id="O2" value="82" lower_limit="74.8" upper_limit="88.5"/>
                    <measurement group_id="O3" value="89" lower_limit="82" upper_limit="94.1"/>
                    <measurement group_id="O4" value="2" lower_limit="0.24" upper_limit="7"/>
                    <measurement group_id="O5" value="73" lower_limit="60.9" upper_limit="83.2"/>
                    <measurement group_id="O6" value="4" lower_limit="0.44" upper_limit="12.5"/>
                    <measurement group_id="O7" value="66" lower_limit="59.1" upper_limit="73.3"/>
                    <measurement group_id="O8" value="6" lower_limit="1.3" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=140;131;119;100;67;55;179;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="14.9" upper_limit="29.2"/>
                    <measurement group_id="O2" value="18" lower_limit="12.1" upper_limit="26"/>
                    <measurement group_id="O3" value="29" lower_limit="20.7" upper_limit="37.6"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="3.6"/>
                    <measurement group_id="O5" value="15" lower_limit="7.3" upper_limit="25.4"/>
                    <measurement group_id="O6" value="2" lower_limit="0.05" upper_limit="9.7"/>
                    <measurement group_id="O7" value="28" lower_limit="21.5" upper_limit="35.1"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N=127;111;109;93;65;53;173;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="16.5" upper_limit="32"/>
                    <measurement group_id="O2" value="22" lower_limit="14.4" upper_limit="30.4"/>
                    <measurement group_id="O3" value="28" lower_limit="20.2" upper_limit="37.9"/>
                    <measurement group_id="O4" value="26" lower_limit="17.3" upper_limit="35.9"/>
                    <measurement group_id="O5" value="31" lower_limit="19.9" upper_limit="43.4"/>
                    <measurement group_id="O6" value="36" lower_limit="23.1" upper_limit="50.2"/>
                    <measurement group_id="O7" value="54" lower_limit="46" upper_limit="61.4"/>
                    <measurement group_id="O8" value="49" lower_limit="34.4" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains</title>
        <description>The hSBA antibody titers in subjects, 24 to 36 months after completion of Bexsero® vaccination course according to different schedules in the parent study, are presented in terms of vaccine-group-specific GMTs, alongside with the corresponding antibody responses in age-matched vaccine-naïve subjects at baseline.</description>
        <time_frame>24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects</time_frame>
        <population>Analysis was done on FAS-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511</title>
            <description>Combined group 4D_2-11M/B + group 4D_2-11M - Subjects who received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O2">
            <title>3H5_11</title>
            <description>Combined group 3D_3-11M/B + group 3D_3-11M - Subjects who received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O3">
            <title>68_11</title>
            <description>Combined group 3D_6-11Y/B + group 3D_6-11M - Subjects who received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O4">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O5">
            <title>02_2_5</title>
            <description>Combined group 2D_2-5Y/B + group 2D_2-5Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 2 and 5 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O6">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O7">
            <title>02_6_10</title>
            <description>Combined group 2D_6-10Y/B + group 2D_6-10Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 6 and 10 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study V72_28 (NCT01894919).</description>
          </group>
        </group_list>
        <measure>
          <title>The hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains</title>
          <description>The hSBA antibody titers in subjects, 24 to 36 months after completion of Bexsero® vaccination course according to different schedules in the parent study, are presented in terms of vaccine-group-specific GMTs, alongside with the corresponding antibody responses in age-matched vaccine-naïve subjects at baseline.</description>
          <population>Analysis was done on FAS-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="179"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (N=140;131;119;100;67;55;178;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="3.4" upper_limit="5.13"/>
                    <measurement group_id="O2" value="4.48" lower_limit="3.6" upper_limit="5.57"/>
                    <measurement group_id="O3" value="5.62" lower_limit="4.48" upper_limit="7.04"/>
                    <measurement group_id="O4" value="2.79" lower_limit="2.25" upper_limit="3.45"/>
                    <measurement group_id="O5" value="3.97" lower_limit="2.99" upper_limit="5.28"/>
                    <measurement group_id="O6" value="2.33" lower_limit="1.77" upper_limit="3.07"/>
                    <measurement group_id="O7" value="5.75" lower_limit="4.78" upper_limit="6.91"/>
                    <measurement group_id="O8" value="1.93" lower_limit="1.39" upper_limit="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N=140;131;119;100;67;55;179;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="32" upper_limit="60"/>
                    <measurement group_id="O2" value="52" lower_limit="37" upper_limit="72"/>
                    <measurement group_id="O3" value="83" lower_limit="58" upper_limit="117"/>
                    <measurement group_id="O4" value="1.15" lower_limit="1.03" upper_limit="1.29"/>
                    <measurement group_id="O5" value="21" lower_limit="14" upper_limit="33"/>
                    <measurement group_id="O6" value="1.2" lower_limit="0.96" upper_limit="1.51"/>
                    <measurement group_id="O7" value="21" lower_limit="16" upper_limit="28"/>
                    <measurement group_id="O8" value="1.38" lower_limit="1.1" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=140;131;119;100;67;55;179;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" lower_limit="2.78" upper_limit="4.36"/>
                    <measurement group_id="O2" value="2.98" lower_limit="2.35" upper_limit="3.78"/>
                    <measurement group_id="O3" value="4.86" lower_limit="3.8" upper_limit="6.22"/>
                    <measurement group_id="O4" value="1.14" lower_limit="1.06" upper_limit="1.22"/>
                    <measurement group_id="O5" value="2.81" lower_limit="2.07" upper_limit="3.82"/>
                    <measurement group_id="O6" value="1.37" lower_limit="1.17" upper_limit="1.61"/>
                    <measurement group_id="O7" value="4.57" lower_limit="3.74" upper_limit="5.59"/>
                    <measurement group_id="O8" value="1.22" lower_limit="1.06" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N=127;111;109;93;65;53;173;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" lower_limit="2.06" upper_limit="3.71"/>
                    <measurement group_id="O2" value="3.03" lower_limit="2.2" upper_limit="4.16"/>
                    <measurement group_id="O3" value="3.17" lower_limit="2.3" upper_limit="4.38"/>
                    <measurement group_id="O4" value="3.3" lower_limit="2.52" upper_limit="4.32"/>
                    <measurement group_id="O5" value="3.53" lower_limit="2.38" upper_limit="5.25"/>
                    <measurement group_id="O6" value="4.26" lower_limit="2.61" upper_limit="6.97"/>
                    <measurement group_id="O7" value="7.82" lower_limit="6.04" upper_limit="10"/>
                    <measurement group_id="O8" value="6.95" lower_limit="4.18" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus 1 Month After Completion of Bexsero® Vaccination Course According to Different Schedules in the Parent Study.</title>
        <description>The within-subjects GMR of GMTs at 24 to 36 months versus 1 month after completion of Bexsero® vaccination course according to different schedules vaccination in parent study are reported.</description>
        <time_frame>At Day 1 in this study over one month after the completion of the vaccination course in the parent study</time_frame>
        <population>Analysis was done on FAS-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511</title>
            <description>Combined group 4D_2-11M/B + group 4D_2-11M - Subjects who received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O2">
            <title>3H5_11</title>
            <description>Combined group 3D_3-11M/B + group 3D_3-11M - Subjects who received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O3">
            <title>68_11</title>
            <description>Combined group 3D_6-11Y/B + group 3D_6-11M - Subjects who received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O4">
            <title>02_2_5</title>
            <description>Combined group 2D_2-5Y/B + group 2D_2-5Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 2 and 5 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O5">
            <title>02_6_10</title>
            <description>Combined group 2D_6-10Y/B + group 2D_6-10Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 6 and 10 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus 1 Month After Completion of Bexsero® Vaccination Course According to Different Schedules in the Parent Study.</title>
          <description>The within-subjects GMR of GMTs at 24 to 36 months versus 1 month after completion of Bexsero® vaccination course according to different schedules vaccination in parent study are reported.</description>
          <population>Analysis was done on FAS-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1. The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (N=137;129;118;67;173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" lower_limit="0.023" upper_limit="0.036"/>
                    <measurement group_id="O2" value="0.022" lower_limit="0.017" upper_limit="0.028"/>
                    <measurement group_id="O3" value="0.03" lower_limit="0.023" upper_limit="0.038"/>
                    <measurement group_id="O4" value="0.028" lower_limit="0.021" upper_limit="0.038"/>
                    <measurement group_id="O5" value="0.042" lower_limit="0.035" upper_limit="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N=136;130;118;66;176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" lower_limit="0.017" upper_limit="0.03"/>
                    <measurement group_id="O2" value="0.031" lower_limit="0.023" upper_limit="0.041"/>
                    <measurement group_id="O3" value="0.054" lower_limit="0.04" upper_limit="0.073"/>
                    <measurement group_id="O4" value="0.045" lower_limit="0.031" upper_limit="0.066"/>
                    <measurement group_id="O5" value="0.049" lower_limit="0.038" upper_limit="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=136;129;116;68;174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.059" lower_limit="0.047" upper_limit="0.074"/>
                    <measurement group_id="O2" value="0.038" lower_limit="0.03" upper_limit="0.048"/>
                    <measurement group_id="O3" value="0.07" lower_limit="0.055" upper_limit="0.09"/>
                    <measurement group_id="O4" value="0.061" lower_limit="0.044" upper_limit="0.083"/>
                    <measurement group_id="O5" value="0.095" lower_limit="0.077" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N=105;84;78;61;160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.13" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.11" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.19" lower_limit="0.12" upper_limit="0.29"/>
                    <measurement group_id="O4" value="0.17" lower_limit="0.11" upper_limit="0.28"/>
                    <measurement group_id="O5" value="0.24" lower_limit="0.17" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus Visit 1 in the Parent Study.</title>
        <description>The within-subjects GMR of GMTs at 24 to 36 months versus visit 1 in the vaccination course according to different schedules vaccination in the parent study are reported.</description>
        <time_frame>At Day 1 in this study over visit 1 in the vaccination course in the parent study</time_frame>
        <population>Analysis was done on FAS-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1.This outcome measure applies to only groups 02_2_5 &amp; 02_6_10 as the GMRs were calculated at 24-36 months after completion of vaccination course in the parent study over subjects belonging to groups 02_2_5 &amp; 02_6_10.</population>
        <group_list>
          <group group_id="O1">
            <title>02_2_5</title>
            <description>Combined group 2D_2-5Y/B + group 2D_2-5Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 2 and 5 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
          <group group_id="O2">
            <title>02_6_10</title>
            <description>Combined group 2D_6-10Y/B + group 2D_6-10Y- Subjects who received two catch-up doses of Bexsero® vaccine two months apart, at 6 and 10 years of age, respectively, in the parent study V72_28 (NCT01894919).</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus Visit 1 in the Parent Study.</title>
          <description>The within-subjects GMR of GMTs at 24 to 36 months versus visit 1 in the vaccination course according to different schedules vaccination in the parent study are reported.</description>
          <population>Analysis was done on FAS-persistence: All subjects in the Enrolled Set who provide an evaluable serum sample at Visit 1.This outcome measure applies to only groups 02_2_5 &amp; 02_6_10 as the GMRs were calculated at 24-36 months after completion of vaccination course in the parent study over subjects belonging to groups 02_2_5 &amp; 02_6_10.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (N=67;177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" lower_limit="1.32" upper_limit="2.69"/>
                    <measurement group_id="O2" value="2.94" lower_limit="2.33" upper_limit="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N=67;177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="12" upper_limit="32"/>
                    <measurement group_id="O2" value="14" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=67;177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="1.76" upper_limit="3.49"/>
                    <measurement group_id="O2" value="3.06" lower_limit="2.44" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N=56;163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.49" upper_limit="1.61"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.64" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titers ≥4 or ≥ 5 Against N.Meningitidis Serogroup B, After Receiving Bexsero® Booster Vaccination in This Study.</title>
        <description>The percentage of subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and with hSBA titers ≥ 5 against M10713 strain, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study), alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.</description>
        <time_frame>At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)</time_frame>
        <population>Analysis was done on FAS - booster: All subjects in the Enrolled Set who receive a study vaccination and provide an evaluable serum sample at visit 2 (one month after the booster dose administration) and received all scheduled vaccinations in the parent study V72_28 (excluding naïve groups).</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3H5_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O3">
            <title>68_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O4">
            <title>02_2_5_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O5">
            <title>02_6_10_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O6">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O7">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titers ≥4 or ≥ 5 Against N.Meningitidis Serogroup B, After Receiving Bexsero® Booster Vaccination in This Study.</title>
          <description>The percentage of subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and with hSBA titers ≥ 5 against M10713 strain, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study), alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.</description>
          <population>Analysis was done on FAS - booster: All subjects in the Enrolled Set who receive a study vaccination and provide an evaluable serum sample at visit 2 (one month after the booster dose administration) and received all scheduled vaccinations in the parent study V72_28 (excluding naïve groups).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (pre-vacc.) (N=92;86;75;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="37.3" upper_limit="58.5"/>
                    <measurement group_id="O2" value="51" lower_limit="40.1" upper_limit="62.1"/>
                    <measurement group_id="O3" value="64" lower_limit="52.1" upper_limit="74.8"/>
                    <measurement group_id="O4" value="39" lower_limit="21.8" upper_limit="57.8"/>
                    <measurement group_id="O5" value="59" lower_limit="48.5" upper_limit="69.5"/>
                    <measurement group_id="O6" value="39" lower_limit="28.8" upper_limit="49"/>
                    <measurement group_id="O7" value="27" lower_limit="16.1" upper_limit="41"/>
                    <measurement group_id="O8" value="20" lower_limit="10" upper_limit="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (post-vacc.) (N=96;86;75;32;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.3" upper_limit="99.97"/>
                    <measurement group_id="O2" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95.2" upper_limit="100"/>
                    <measurement group_id="O4" value="97" lower_limit="83.8" upper_limit="99.92"/>
                    <measurement group_id="O5" value="99" lower_limit="94" upper_limit="99.97"/>
                    <measurement group_id="O6" value="95" lower_limit="88.3" upper_limit="98.3"/>
                    <measurement group_id="O7" value="91" lower_limit="80" upper_limit="97"/>
                    <measurement group_id="O8" value="80" lower_limit="66.3" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (pre-vacc.) (N=92;87;76;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="74.5" upper_limit="90.6"/>
                    <measurement group_id="O2" value="91" lower_limit="82.7" upper_limit="95.9"/>
                    <measurement group_id="O3" value="95" lower_limit="87.1" upper_limit="98.5"/>
                    <measurement group_id="O4" value="74" lower_limit="55.4" upper_limit="88.1"/>
                    <measurement group_id="O5" value="86" lower_limit="76.8" upper_limit="92.2"/>
                    <measurement group_id="O6" value="3" lower_limit="0.6" upper_limit="8.9"/>
                    <measurement group_id="O7" value="4" lower_limit="0.44" upper_limit="12.5"/>
                    <measurement group_id="O8" value="8" lower_limit="2.2" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (post-vacc.) (N=96;87;76;32;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.3" upper_limit="99.97"/>
                    <measurement group_id="O2" value="99" lower_limit="93.8" upper_limit="99.97"/>
                    <measurement group_id="O3" value="97" lower_limit="90.8" upper_limit="99.68"/>
                    <measurement group_id="O4" value="100" lower_limit="89.1" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O6" value="88" lower_limit="79.2" upper_limit="93.4"/>
                    <measurement group_id="O7" value="93" lower_limit="82.4" upper_limit="98"/>
                    <measurement group_id="O8" value="80" lower_limit="66.3" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (pre-vacc.) (N=92;86;75;32;91;96;54;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="34.2" upper_limit="55.3"/>
                    <measurement group_id="O2" value="42" lower_limit="31.3" upper_limit="53"/>
                    <measurement group_id="O3" value="52" lower_limit="40.2" upper_limit="63.7"/>
                    <measurement group_id="O4" value="25" lower_limit="11.5" upper_limit="43.4"/>
                    <measurement group_id="O5" value="47" lower_limit="36.7" upper_limit="58"/>
                    <measurement group_id="O6" value="2" lower_limit="0.25" upper_limit="7.3"/>
                    <measurement group_id="O7" value="7" lower_limit="2.1" upper_limit="17.9"/>
                    <measurement group_id="O8" value="6" lower_limit="1.3" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (post-vacc.) (N=96;86;75;32;91;96;54;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.3" upper_limit="99.97"/>
                    <measurement group_id="O2" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="89.1" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O6" value="78" lower_limit="68.5" upper_limit="85.9"/>
                    <measurement group_id="O7" value="85" lower_limit="72.9" upper_limit="93.4"/>
                    <measurement group_id="O8" value="70" lower_limit="55.4" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (pre-vacc.) (N=78;68;65;29;87;84;49;46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="25.3" upper_limit="47.6"/>
                    <measurement group_id="O2" value="35" lower_limit="24.1" upper_limit="47.8"/>
                    <measurement group_id="O3" value="45" lower_limit="32.3" upper_limit="57.5"/>
                    <measurement group_id="O4" value="21" lower_limit="8" upper_limit="39.7"/>
                    <measurement group_id="O5" value="63" lower_limit="52.2" upper_limit="73.3"/>
                    <measurement group_id="O6" value="39" lower_limit="28.8" upper_limit="50.5"/>
                    <measurement group_id="O7" value="41" lower_limit="27" upper_limit="55.8"/>
                    <measurement group_id="O8" value="59" lower_limit="43.2" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (post-vacc.) (N=88;79;67;30;89;88;51;47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="59.8" upper_limit="79.7"/>
                    <measurement group_id="O2" value="81" lower_limit="70.6" upper_limit="89"/>
                    <measurement group_id="O3" value="97" lower_limit="89.6" upper_limit="99.64"/>
                    <measurement group_id="O4" value="97" lower_limit="77.9" upper_limit="99.2"/>
                    <measurement group_id="O5" value="96" lower_limit="88.9" upper_limit="98.8"/>
                    <measurement group_id="O6" value="47" lower_limit="35.9" upper_limit="57.5"/>
                    <measurement group_id="O7" value="59" lower_limit="44.2" upper_limit="72.4"/>
                    <measurement group_id="O8" value="60" lower_limit="44.3" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis serogroupB, After Receiving Bexsero® Booster Vaccination in This Study.</title>
        <description>The percentage of subjects with hSBA titers ≥ 8, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.</description>
        <time_frame>At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)</time_frame>
        <population>Analysis was done on FAS-booster:All subjects in the Enrolled Set who receive a study vaccination &amp; provide an evaluable serum sample at visit 2(1 month post booster dose) &amp; received all scheduled vaccinations in V72_28 (excluding naïve groups).The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3H5_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O3">
            <title>68_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O4">
            <title>02_2_5_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O5">
            <title>02_6_10_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O6">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O7">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis serogroupB, After Receiving Bexsero® Booster Vaccination in This Study.</title>
          <description>The percentage of subjects with hSBA titers ≥ 8, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.</description>
          <population>Analysis was done on FAS-booster:All subjects in the Enrolled Set who receive a study vaccination &amp; provide an evaluable serum sample at visit 2(1 month post booster dose) &amp; received all scheduled vaccinations in V72_28 (excluding naïve groups).The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (pre-vacc.) (N=92;86;75;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="17.5" upper_limit="36.3"/>
                    <measurement group_id="O2" value="31" lower_limit="21.8" upper_limit="42.3"/>
                    <measurement group_id="O3" value="33" lower_limit="22.9" upper_limit="45.2"/>
                    <measurement group_id="O4" value="19" lower_limit="7.5" upper_limit="37.5"/>
                    <measurement group_id="O5" value="30" lower_limit="20.5" upper_limit="40.2"/>
                    <measurement group_id="O6" value="18" lower_limit="10.7" upper_limit="26.8"/>
                    <measurement group_id="O7" value="16" lower_limit="7.8" upper_limit="28.8"/>
                    <measurement group_id="O8" value="10" lower_limit="3.3" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (post-vacc.) (N=96;86;75;32;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="91.1" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98" lower_limit="91.9" upper_limit="99.72"/>
                    <measurement group_id="O3" value="99" lower_limit="92.8" upper_limit="99.97"/>
                    <measurement group_id="O4" value="97" lower_limit="83.8" upper_limit="99.92"/>
                    <measurement group_id="O5" value="97" lower_limit="90.7" upper_limit="99.3"/>
                    <measurement group_id="O6" value="68" lower_limit="57.4" upper_limit="76.9"/>
                    <measurement group_id="O7" value="71" lower_limit="57.1" upper_limit="82.4"/>
                    <measurement group_id="O8" value="60" lower_limit="45.2" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (pre-vacc.) (N=92;87;76;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="69.6" upper_limit="87.1"/>
                    <measurement group_id="O2" value="85" lower_limit="75.8" upper_limit="91.8"/>
                    <measurement group_id="O3" value="91" lower_limit="81.9" upper_limit="96.2"/>
                    <measurement group_id="O4" value="71" lower_limit="52" upper_limit="85.8"/>
                    <measurement group_id="O5" value="68" lower_limit="57.5" upper_limit="77.5"/>
                    <measurement group_id="O6" value="2" lower_limit="0.25" upper_limit="7.3"/>
                    <measurement group_id="O7" value="4" lower_limit="0.44" upper_limit="12.5"/>
                    <measurement group_id="O8" value="6" lower_limit="1.3" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (post-vacc.) (N=96;87;76;32;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.3" upper_limit="99.97"/>
                    <measurement group_id="O2" value="99" lower_limit="93.8" upper_limit="99.97"/>
                    <measurement group_id="O3" value="97" lower_limit="90.8" upper_limit="99.68"/>
                    <measurement group_id="O4" value="100" lower_limit="89.1" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O6" value="77" lower_limit="67.4" upper_limit="85"/>
                    <measurement group_id="O7" value="78" lower_limit="65" upper_limit="88.2"/>
                    <measurement group_id="O8" value="60" lower_limit="45.2" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (pre-vacc.) (N=92;86;75;32;91;96;54;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="13.8" upper_limit="31.6"/>
                    <measurement group_id="O2" value="19" lower_limit="11" upper_limit="28.4"/>
                    <measurement group_id="O3" value="28" lower_limit="18.2" upper_limit="39.6"/>
                    <measurement group_id="O4" value="13" lower_limit="3.5" upper_limit="29"/>
                    <measurement group_id="O5" value="26" lower_limit="17.7" upper_limit="36.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="3.8"/>
                    <measurement group_id="O7" value="2" lower_limit="0.05" upper_limit="9.9"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/54 (post-vacc.) (N=96;86;75;32;91;96;54;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="91.1" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98" lower_limit="91.9" upper_limit="99.72"/>
                    <measurement group_id="O3" value="100" lower_limit="95.2" upper_limit="100"/>
                    <measurement group_id="O4" value="97" lower_limit="83.8" upper_limit="99.92"/>
                    <measurement group_id="O5" value="97" lower_limit="90.7" upper_limit="99.3"/>
                    <measurement group_id="O6" value="34" lower_limit="25" upper_limit="44.8"/>
                    <measurement group_id="O7" value="54" lower_limit="39.6" upper_limit="67.4"/>
                    <measurement group_id="O8" value="40" lower_limit="26.4" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (pre-vacc.) (N=78;68;65;29;87;84;49;46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="18.6" upper_limit="39.5"/>
                    <measurement group_id="O2" value="22" lower_limit="12.9" upper_limit="33.8"/>
                    <measurement group_id="O3" value="34" lower_limit="22.6" upper_limit="46.6"/>
                    <measurement group_id="O4" value="17" lower_limit="5.8" upper_limit="35.8"/>
                    <measurement group_id="O5" value="55" lower_limit="44.1" upper_limit="65.9"/>
                    <measurement group_id="O6" value="27" lower_limit="18.2" upper_limit="38.2"/>
                    <measurement group_id="O7" value="39" lower_limit="25.2" upper_limit="53.8"/>
                    <measurement group_id="O8" value="52" lower_limit="36.9" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (post-vacc.) (N=88;79;67;30;89;88;51;47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="52.7" upper_limit="73.6"/>
                    <measurement group_id="O2" value="71" lower_limit="59.6" upper_limit="80.6"/>
                    <measurement group_id="O3" value="94" lower_limit="85.4" upper_limit="98.3"/>
                    <measurement group_id="O4" value="90" lower_limit="73.5" upper_limit="97.9"/>
                    <measurement group_id="O5" value="92" lower_limit="84.5" upper_limit="96.8"/>
                    <measurement group_id="O6" value="34" lower_limit="24.3" upper_limit="45"/>
                    <measurement group_id="O7" value="51" lower_limit="36.6" upper_limit="65.2"/>
                    <measurement group_id="O8" value="57" lower_limit="42.2" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Bexsero® Vaccination in This Study.</title>
        <description>The percentage of subjects with a four-fold rise in hSBA titers after receiving Bexsero® booster vaccination in this study to pre vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.</description>
        <time_frame>One month after booster vaccination (day 31)/24-36 months (Visit 1)</time_frame>
        <population>Analysis was done on FAS-booster:All subjects in the Enrolled Set who receive a study vaccination &amp; provide an evaluable serum sample at visit 2(1 month post booster dose) &amp; received all scheduled vaccinations in V72_28 (excluding naïve groups).The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3H5_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O3">
            <title>68_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O4">
            <title>02_2_5_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O5">
            <title>02_6_10_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O6">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O7">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Bexsero® Vaccination in This Study.</title>
          <description>The percentage of subjects with a four-fold rise in hSBA titers after receiving Bexsero® booster vaccination in this study to pre vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.</description>
          <population>Analysis was done on FAS-booster:All subjects in the Enrolled Set who receive a study vaccination &amp; provide an evaluable serum sample at visit 2(1 month post booster dose) &amp; received all scheduled vaccinations in V72_28 (excluding naïve groups).The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (Day 31/PRE) (N=92;86;75;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="87.8" upper_limit="98.2"/>
                    <measurement group_id="O2" value="95" lower_limit="88.5" upper_limit="98.7"/>
                    <measurement group_id="O3" value="97" lower_limit="90.7" upper_limit="99.68"/>
                    <measurement group_id="O4" value="94" lower_limit="78.6" upper_limit="99.2"/>
                    <measurement group_id="O5" value="97" lower_limit="90.7" upper_limit="99.3"/>
                    <measurement group_id="O6" value="43" lower_limit="32.7" upper_limit="53.2"/>
                    <measurement group_id="O7" value="53" lower_limit="38.8" upper_limit="66.3"/>
                    <measurement group_id="O8" value="46" lower_limit="31.8" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 31/PRE) (N=92;87;76;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="92.4" upper_limit="99.74"/>
                    <measurement group_id="O2" value="98" lower_limit="91.9" upper_limit="99.72"/>
                    <measurement group_id="O3" value="95" lower_limit="87.1" upper_limit="98.5"/>
                    <measurement group_id="O4" value="100" lower_limit="88.8" upper_limit="100"/>
                    <measurement group_id="O5" value="98" lower_limit="92.3" upper_limit="99.73"/>
                    <measurement group_id="O6" value="77" lower_limit="67.4" upper_limit="85"/>
                    <measurement group_id="O7" value="76" lower_limit="63" upper_limit="86.8"/>
                    <measurement group_id="O8" value="60" lower_limit="45.2" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 31/PRE) (N=92;86;75;32;91;96;54;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="84.9" upper_limit="96.9"/>
                    <measurement group_id="O2" value="95" lower_limit="88.5" upper_limit="98.7"/>
                    <measurement group_id="O3" value="93" lower_limit="85.1" upper_limit="97.8"/>
                    <measurement group_id="O4" value="94" lower_limit="79.2" upper_limit="99.2"/>
                    <measurement group_id="O5" value="86" lower_limit="76.8" upper_limit="92.2"/>
                    <measurement group_id="O6" value="34" lower_limit="25" upper_limit="44.8"/>
                    <measurement group_id="O7" value="54" lower_limit="39.6" upper_limit="67.4"/>
                    <measurement group_id="O8" value="40" lower_limit="26.4" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (Day 31/PRE) (N=78;68;65;29;87;84;49;46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="30" upper_limit="52.7"/>
                    <measurement group_id="O2" value="50" lower_limit="37.6" upper_limit="62.4"/>
                    <measurement group_id="O3" value="68" lower_limit="54.9" upper_limit="78.8"/>
                    <measurement group_id="O4" value="72" lower_limit="52.8" upper_limit="87.3"/>
                    <measurement group_id="O5" value="53" lower_limit="41.9" upper_limit="63.7"/>
                    <measurement group_id="O6" value="11" lower_limit="5" upper_limit="19.4"/>
                    <measurement group_id="O7" value="20" lower_limit="10.2" upper_limit="34.3"/>
                    <measurement group_id="O8" value="13" lower_limit="4.9" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.</title>
        <description>The hSBA antibody titers in subjects after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the 1st dose of Bexsero® vaccine in age matched vaccine-naïve subjects in terms of GMTs.</description>
        <time_frame>At Visit 1 and one month post booster vaccination (Day 31)</time_frame>
        <population>Analysis was done on FAS-Booster:All subjects in the Enrolled Set who receive a study vaccination &amp; provide an evaluable serum sample at visit 2(1 month post booster dose) &amp; received all scheduled vaccinations in V72_28(excluding naïve groups).The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3H5_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O3">
            <title>68_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O4">
            <title>02_2_5_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O5">
            <title>02_6_10_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O6">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O7">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.</title>
          <description>The hSBA antibody titers in subjects after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the 1st dose of Bexsero® vaccine in age matched vaccine-naïve subjects in terms of GMTs.</description>
          <population>Analysis was done on FAS-Booster:All subjects in the Enrolled Set who receive a study vaccination &amp; provide an evaluable serum sample at visit 2(1 month post booster dose) &amp; received all scheduled vaccinations in V72_28(excluding naïve groups).The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (pre-vacc.) (N=92;86;75;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" lower_limit="3.01" upper_limit="5.08"/>
                    <measurement group_id="O2" value="4.84" lower_limit="3.66" upper_limit="6.41"/>
                    <measurement group_id="O3" value="6.21" lower_limit="4.65" upper_limit="8.31"/>
                    <measurement group_id="O4" value="3.14" lower_limit="2.08" upper_limit="4.75"/>
                    <measurement group_id="O5" value="6.15" lower_limit="4.77" upper_limit="7.93"/>
                    <measurement group_id="O6" value="2.82" lower_limit="2.26" upper_limit="3.5"/>
                    <measurement group_id="O7" value="2.33" lower_limit="1.77" upper_limit="3.07"/>
                    <measurement group_id="O8" value="1.93" lower_limit="1.39" upper_limit="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (post-vacc.) (N=96;86;75;32;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" lower_limit="116" upper_limit="215"/>
                    <measurement group_id="O2" value="205" lower_limit="147" upper_limit="287"/>
                    <measurement group_id="O3" value="288" lower_limit="204" upper_limit="408"/>
                    <measurement group_id="O4" value="155" lower_limit="95" upper_limit="252"/>
                    <measurement group_id="O5" value="258" lower_limit="190" upper_limit="349"/>
                    <measurement group_id="O6" value="14" lower_limit="11" upper_limit="17"/>
                    <measurement group_id="O7" value="16" lower_limit="12" upper_limit="23"/>
                    <measurement group_id="O8" value="13" lower_limit="8.67" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (pre-vacc.) (N=92;87;76;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="26" upper_limit="58"/>
                    <measurement group_id="O2" value="53" lower_limit="35" upper_limit="82"/>
                    <measurement group_id="O3" value="89" lower_limit="57" upper_limit="139"/>
                    <measurement group_id="O4" value="19" lower_limit="9.92" upper_limit="35"/>
                    <measurement group_id="O5" value="22" lower_limit="15" upper_limit="32"/>
                    <measurement group_id="O6" value="1.15" lower_limit="1.02" upper_limit="1.29"/>
                    <measurement group_id="O7" value="1.2" lower_limit="0.96" upper_limit="1.51"/>
                    <measurement group_id="O8" value="1.38" lower_limit="1.1" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (post-vacc.) (N=96;87;76;32;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2908" lower_limit="2059" upper_limit="4107"/>
                    <measurement group_id="O2" value="3593" lower_limit="2474" upper_limit="5218"/>
                    <measurement group_id="O3" value="3677" lower_limit="2495" upper_limit="5419"/>
                    <measurement group_id="O4" value="3205" lower_limit="1860" upper_limit="5526"/>
                    <measurement group_id="O5" value="2921" lower_limit="2079" upper_limit="4104"/>
                    <measurement group_id="O6" value="38" lower_limit="28" upper_limit="54"/>
                    <measurement group_id="O7" value="27" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="O8" value="20" lower_limit="12" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (pre-vacc.) (N=92;86;75;32;91;96;54;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" lower_limit="2.57" upper_limit="4.54"/>
                    <measurement group_id="O2" value="3.17" lower_limit="2.34" upper_limit="4.31"/>
                    <measurement group_id="O3" value="4.86" lower_limit="3.54" upper_limit="6.67"/>
                    <measurement group_id="O4" value="2.99" lower_limit="1.92" upper_limit="4.65"/>
                    <measurement group_id="O5" value="4.49" lower_limit="3.4" upper_limit="5.92"/>
                    <measurement group_id="O6" value="1.14" lower_limit="1.06" upper_limit="1.23"/>
                    <measurement group_id="O7" value="1.35" lower_limit="1.15" upper_limit="1.59"/>
                    <measurement group_id="O8" value="1.22" lower_limit="1.06" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (post-vacc.) (N=96;86;75;32;91;96;54;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="70" upper_limit="122"/>
                    <measurement group_id="O2" value="91" lower_limit="68" upper_limit="123"/>
                    <measurement group_id="O3" value="133" lower_limit="97" upper_limit="181"/>
                    <measurement group_id="O4" value="71" lower_limit="46" upper_limit="110"/>
                    <measurement group_id="O5" value="82" lower_limit="63" upper_limit="108"/>
                    <measurement group_id="O6" value="6.94" lower_limit="5.6" upper_limit="8.59"/>
                    <measurement group_id="O7" value="13" lower_limit="8.88" upper_limit="19"/>
                    <measurement group_id="O8" value="8.56" lower_limit="5.51" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (pre-vacc.) (N=78;68;65;29;87;84;49;46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="2.08" upper_limit="4.46"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.05" upper_limit="4.68"/>
                    <measurement group_id="O3" value="3.58" lower_limit="2.35" upper_limit="5.45"/>
                    <measurement group_id="O4" value="2.31" lower_limit="1.29" upper_limit="4.13"/>
                    <measurement group_id="O5" value="7.83" lower_limit="5.52" upper_limit="11"/>
                    <measurement group_id="O6" value="3.53" lower_limit="2.64" upper_limit="4.71"/>
                    <measurement group_id="O7" value="4.8" lower_limit="2.86" upper_limit="8.06"/>
                    <measurement group_id="O8" value="7.7" lower_limit="4.55" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (post-vacc.) (N=88;79;67;30;89;88;51;47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9.15" upper_limit="18"/>
                    <measurement group_id="O2" value="18" lower_limit="13" upper_limit="26"/>
                    <measurement group_id="O3" value="40" lower_limit="27" upper_limit="59"/>
                    <measurement group_id="O4" value="32" lower_limit="19" upper_limit="54"/>
                    <measurement group_id="O5" value="53" lower_limit="38" upper_limit="73"/>
                    <measurement group_id="O6" value="4.92" lower_limit="3.39" upper_limit="7.13"/>
                    <measurement group_id="O7" value="9.44" lower_limit="5.84" upper_limit="15"/>
                    <measurement group_id="O8" value="12" lower_limit="6.61" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.</title>
        <description>The within-subjects GMR of hSBA antibody titers (one month post booster vaccination versus pre vaccination) after Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the within-subject GMR for the 1st dose of rMenB+OMV NZ vaccination of age matched naïve subjects.</description>
        <time_frame>Day 1 and Day 31</time_frame>
        <population>Analysis was done on FAS-Booster:All subjects in the Enrolled Set who receive a study vaccination &amp; provide an evaluable serum sample at visit 2 (1 month post booster dose) &amp; received all scheduled vaccinations in V72_28 (excluding naïve groups). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3H5_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O3">
            <title>68_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O4">
            <title>02_2_5_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O5">
            <title>02_6_10_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O6">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O7">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.</title>
          <description>The within-subjects GMR of hSBA antibody titers (one month post booster vaccination versus pre vaccination) after Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the within-subject GMR for the 1st dose of rMenB+OMV NZ vaccination of age matched naïve subjects.</description>
          <population>Analysis was done on FAS-Booster:All subjects in the Enrolled Set who receive a study vaccination &amp; provide an evaluable serum sample at visit 2 (1 month post booster dose) &amp; received all scheduled vaccinations in V72_28 (excluding naïve groups). The number of participants analyzed is the number of subjects assessed for this particular endpoint.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="96"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (Day 31/PRE) (N=92;86;75;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="30" upper_limit="55"/>
                    <measurement group_id="O2" value="43" lower_limit="31" upper_limit="59"/>
                    <measurement group_id="O3" value="46" lower_limit="33" upper_limit="65"/>
                    <measurement group_id="O4" value="50" lower_limit="31" upper_limit="80"/>
                    <measurement group_id="O5" value="42" lower_limit="31" upper_limit="56"/>
                    <measurement group_id="O6" value="4.81" lower_limit="3.81" upper_limit="6.07"/>
                    <measurement group_id="O7" value="7.08" lower_limit="5.07" upper_limit="9.88"/>
                    <measurement group_id="O8" value="6.87" lower_limit="4.62" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 31/PRE) (N=92;87;76;31;91;96;55;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="54" upper_limit="104"/>
                    <measurement group_id="O2" value="67" lower_limit="47" upper_limit="96"/>
                    <measurement group_id="O3" value="41" lower_limit="29" upper_limit="60"/>
                    <measurement group_id="O4" value="160" lower_limit="95" upper_limit="270"/>
                    <measurement group_id="O5" value="135" lower_limit="98" upper_limit="186"/>
                    <measurement group_id="O6" value="34" lower_limit="24" upper_limit="46"/>
                    <measurement group_id="O7" value="22" lower_limit="15" upper_limit="34"/>
                    <measurement group_id="O8" value="14" lower_limit="9.11" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 31/PRE)(N=92;86;75;32;91;96;54;50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="20" upper_limit="38"/>
                    <measurement group_id="O2" value="29" lower_limit="21" upper_limit="41"/>
                    <measurement group_id="O3" value="27" lower_limit="19" upper_limit="39"/>
                    <measurement group_id="O4" value="24" lower_limit="15" upper_limit="40"/>
                    <measurement group_id="O5" value="18" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="O6" value="6.07" lower_limit="4.97" upper_limit="7.41"/>
                    <measurement group_id="O7" value="9.58" lower_limit="6.8" upper_limit="13"/>
                    <measurement group_id="O8" value="7.01" lower_limit="4.54" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (Day 31/PRE) (N=78;68;65;29;87;84;49;46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" lower_limit="2.8" upper_limit="5.91"/>
                    <measurement group_id="O2" value="5.65" lower_limit="3.77" upper_limit="8.47"/>
                    <measurement group_id="O3" value="11" lower_limit="7.15" upper_limit="16"/>
                    <measurement group_id="O4" value="13" lower_limit="7.29" upper_limit="23"/>
                    <measurement group_id="O5" value="6.85" lower_limit="4.86" upper_limit="9.66"/>
                    <measurement group_id="O6" value="1.38" lower_limit="1.01" upper_limit="1.88"/>
                    <measurement group_id="O7" value="2.06" lower_limit="1.36" upper_limit="3.12"/>
                    <measurement group_id="O8" value="1.55" lower_limit="1.1" upper_limit="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titers ≥ 4 or ≥ 5, After Receiving Two Catch up Doses of Bexsero® Vaccination</title>
        <description>The percentage of vaccine-naïve subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and ≥ 5 against M10713 strain, one month after receiving two catch up doses of Bexsero® booster vaccination in this study.</description>
        <time_frame>At Baseline and One month post second vaccination (Day 61)</time_frame>
        <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
        <group_list>
          <group group_id="O1">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O2">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O3">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titers ≥ 4 or ≥ 5, After Receiving Two Catch up Doses of Bexsero® Vaccination</title>
          <description>The percentage of vaccine-naïve subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and ≥ 5 against M10713 strain, one month after receiving two catch up doses of Bexsero® booster vaccination in this study.</description>
          <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (baseline) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="28.2" upper_limit="48.1"/>
                    <measurement group_id="O2" value="26" lower_limit="15" upper_limit="39.7"/>
                    <measurement group_id="O3" value="20" lower_limit="10.2" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 61) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.3" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="90.1" upper_limit="99.95"/>
                    <measurement group_id="O3" value="100" lower_limit="92.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (baseline) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.6" upper_limit="8.7"/>
                    <measurement group_id="O2" value="4" lower_limit="0.45" upper_limit="12.7"/>
                    <measurement group_id="O3" value="6" lower_limit="1.3" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 61) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="92.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (baseline) (N=98;54;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.25" upper_limit="7.2"/>
                    <measurement group_id="O2" value="7" lower_limit="2.1" upper_limit="17.9"/>
                    <measurement group_id="O3" value="6" lower_limit="1.3" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 61) (N=98;54;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="92.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (baseline) (N=87;50;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="24.6" upper_limit="45.4"/>
                    <measurement group_id="O2" value="40" lower_limit="26.4" upper_limit="54.8"/>
                    <measurement group_id="O3" value="55" lower_limit="40.2" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (Day 61) (N=91;52;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="64.5" upper_limit="83.3"/>
                    <measurement group_id="O2" value="69" lower_limit="54.9" upper_limit="81.3"/>
                    <measurement group_id="O3" value="76" lower_limit="61.1" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titers ≥ 8 , After Receiving Two Catch up Doses of Bexsero® Vaccination.</title>
        <description>The percentage of vaccine-naïve subjects with hSBA titers ≥8, one month after receiving two catch up doses of Bexsero® booster vaccination in this study are reported.</description>
        <time_frame>At Baseline and One month post second vaccination (Day 61)</time_frame>
        <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
        <group_list>
          <group group_id="O1">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O2">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O3">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titers ≥ 8 , After Receiving Two Catch up Doses of Bexsero® Vaccination.</title>
          <description>The percentage of vaccine-naïve subjects with hSBA titers ≥8, one month after receiving two catch up doses of Bexsero® booster vaccination in this study are reported.</description>
          <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (baseline) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="10.4" upper_limit="26.3"/>
                    <measurement group_id="O2" value="15" lower_limit="6.6" upper_limit="27.1"/>
                    <measurement group_id="O3" value="10" lower_limit="3.4" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 61) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.4" upper_limit="99.97"/>
                    <measurement group_id="O2" value="96" lower_limit="87.3" upper_limit="99.55"/>
                    <measurement group_id="O3" value="98" lower_limit="89.1" upper_limit="99.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (baseline) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.25" upper_limit="7.2"/>
                    <measurement group_id="O2" value="4" lower_limit="0.45" upper_limit="12.7"/>
                    <measurement group_id="O3" value="4" lower_limit="0.5" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 61) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.4" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="89.1" upper_limit="99.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (baseline) (N=98;54;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.7"/>
                    <measurement group_id="O2" value="2" lower_limit="0.05" upper_limit="9.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 61) (N=98;54;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="89.9" upper_limit="98.9"/>
                    <measurement group_id="O2" value="93" lower_limit="82.1" upper_limit="97.9"/>
                    <measurement group_id="O3" value="94" lower_limit="82.8" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (baseline) (N=87;50;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="16.6" upper_limit="35.7"/>
                    <measurement group_id="O2" value="38" lower_limit="24.7" upper_limit="52.8"/>
                    <measurement group_id="O3" value="49" lower_limit="34.4" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (Day 61) (N=91;52;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="54.1" upper_limit="74.6"/>
                    <measurement group_id="O2" value="63" lower_limit="49" upper_limit="76.4"/>
                    <measurement group_id="O3" value="69" lower_limit="54.6" upper_limit="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Two Catch up Doses of Bexsero® Vaccination.</title>
        <description>The percentage of vaccine-naïve subjects with a four-fold rise in hSBA titers from baseline, one month after receiving two catch up doses of Bexsero® booster vaccination in comparison to prevaccination in this study are reported.</description>
        <time_frame>One month post second vaccination (Day 61)</time_frame>
        <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
        <group_list>
          <group group_id="O1">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O2">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O3">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Two Catch up Doses of Bexsero® Vaccination.</title>
          <description>The percentage of vaccine-naïve subjects with a four-fold rise in hSBA titers from baseline, one month after receiving two catch up doses of Bexsero® booster vaccination in comparison to prevaccination in this study are reported.</description>
          <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="87.1" upper_limit="97.7"/>
                    <measurement group_id="O2" value="89" lower_limit="77.4" upper_limit="95.8"/>
                    <measurement group_id="O3" value="94" lower_limit="83.1" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.4" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="89.1" upper_limit="99.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=98;54;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="87.1" upper_limit="97.7"/>
                    <measurement group_id="O2" value="91" lower_limit="79.7" upper_limit="96.9"/>
                    <measurement group_id="O3" value="94" lower_limit="82.8" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N=87;50;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="26.7" upper_limit="47.8"/>
                    <measurement group_id="O2" value="28" lower_limit="16.2" upper_limit="42.5"/>
                    <measurement group_id="O3" value="22" lower_limit="11.8" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The GMTs in Subjects Who Received Two Catch up Doses of Bexsero® Vaccination.</title>
        <description>The hSBA antibody titers in vaccine-naïve subjects , after receiving two catch up doses of Bexsero® vaccination in this study, are reported in terms of GMTs.</description>
        <time_frame>At Baseline and One month post second vaccination (Day 61)</time_frame>
        <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
        <group_list>
          <group group_id="O1">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O2">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O3">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>The GMTs in Subjects Who Received Two Catch up Doses of Bexsero® Vaccination.</title>
          <description>The hSBA antibody titers in vaccine-naïve subjects , after receiving two catch up doses of Bexsero® vaccination in this study, are reported in terms of GMTs.</description>
          <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (baseline) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.75" upper_limit="3.01"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.55" upper_limit="3"/>
                    <measurement group_id="O3" value="1.56" lower_limit="1.11" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 (Day 61) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" lower_limit="84" upper_limit="135"/>
                    <measurement group_id="O2" value="74" lower_limit="56" upper_limit="99"/>
                    <measurement group_id="O3" value="63" lower_limit="47" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (baseline) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.94" upper_limit="1.36"/>
                    <measurement group_id="O2" value="1.13" lower_limit="0.9" upper_limit="1.41"/>
                    <measurement group_id="O3" value="1.31" lower_limit="1.04" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Day 61) (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="631" lower_limit="503" upper_limit="792"/>
                    <measurement group_id="O2" value="421" lower_limit="319" upper_limit="555"/>
                    <measurement group_id="O3" value="317" lower_limit="238" upper_limit="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (baseline) (N=98;54;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.98" upper_limit="1.26"/>
                    <measurement group_id="O2" value="1.34" lower_limit="1.15" upper_limit="1.56"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.02" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Day 61) (N=98;54;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="27" upper_limit="42"/>
                    <measurement group_id="O2" value="37" lower_limit="28" upper_limit="49"/>
                    <measurement group_id="O3" value="34" lower_limit="26" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (baseline) (N=87;50;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.94" upper_limit="4.34"/>
                    <measurement group_id="O2" value="4.12" lower_limit="2.54" upper_limit="6.69"/>
                    <measurement group_id="O3" value="6.4" lower_limit="3.91" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (Day 61) (N=91;52;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7.57" upper_limit="18"/>
                    <measurement group_id="O2" value="11" lower_limit="6.87" upper_limit="19"/>
                    <measurement group_id="O3" value="14" lower_limit="8.34" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The GMRs of hSBA Titers After Two Catch up Doses of Bexsero® Vaccination Versus hSBA Titers at Baseline.</title>
        <description>The within-subject GMRs of hSBA titers at one month after receiving the second catch up dose to hSBA titers at baseline, for naïve subjects who received two catch up doses of Bexsero® vaccination in this study are reported.</description>
        <time_frame>At Baseline (Day 1)</time_frame>
        <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
        <group_list>
          <group group_id="O1">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O2">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O3">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>The GMRs of hSBA Titers After Two Catch up Doses of Bexsero® Vaccination Versus hSBA Titers at Baseline.</title>
          <description>The within-subject GMRs of hSBA titers at one month after receiving the second catch up dose to hSBA titers at baseline, for naïve subjects who received two catch up doses of Bexsero® vaccination in this study are reported.</description>
          <population>Analysis was done on FAS-catch-up population: All subjects in the Enrolled Set who receive at least one study vaccination and provide evaluable serum samples whose assay results are available on at least one post-baseline visit (visit 1 or visit 2).</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="34" upper_limit="63"/>
                    <measurement group_id="O2" value="34" lower_limit="24" upper_limit="50"/>
                    <measurement group_id="O3" value="41" lower_limit="27" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N=98;54;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="558" lower_limit="423" upper_limit="737"/>
                    <measurement group_id="O2" value="373" lower_limit="266" upper_limit="524"/>
                    <measurement group_id="O3" value="242" lower_limit="171" upper_limit="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=98;54;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="24" upper_limit="39"/>
                    <measurement group_id="O2" value="27" lower_limit="20" upper_limit="37"/>
                    <measurement group_id="O3" value="29" lower_limit="21" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N=87;50;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" lower_limit="2.62" upper_limit="5.69"/>
                    <measurement group_id="O2" value="2.93" lower_limit="1.84" upper_limit="4.67"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.37" upper_limit="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (35 Months to 7 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.</title>
        <description>The number of subjects (35 months to 7 years of age) with solicited local and systemic adverse events after receivingBexsero® booster vaccine in the present study.</description>
        <time_frame>From day 1 (6 hr) through day 7 after vaccination</time_frame>
        <population>Analysis was done on solicited safety set: All subjects in the Exposed Set with solicited adverse event data</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3H5_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O3">
            <title>68_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O4">
            <title>02_2_5_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (35 Months to 7 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.</title>
          <description>The number of subjects (35 months to 7 years of age) with solicited local and systemic adverse events after receivingBexsero® booster vaccine in the present study.</description>
          <population>Analysis was done on solicited safety set: All subjects in the Exposed Set with solicited adverse event data</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;38.0° C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-Attended Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of Pain and/or Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of Pain and/or Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Newly Recruited Subjects (Aged 35 Months to 7 Years) Reporting Solicited Local and Systemic Adverse Events After Receiving Catch-up Doses of Bexsero® Vaccine.</title>
        <description>The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.</description>
        <time_frame>The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study</time_frame>
        <population>Analysis was done on solicited safety set: All subjects in the Exposed Set with solicited adverse event data.</population>
        <group_list>
          <group group_id="O1">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O2">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Newly Recruited Subjects (Aged 35 Months to 7 Years) Reporting Solicited Local and Systemic Adverse Events After Receiving Catch-up Doses of Bexsero® Vaccine.</title>
          <description>The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.</description>
          <population>Analysis was done on solicited safety set: All subjects in the Exposed Set with solicited adverse event data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local AEs (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic AEs (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;38.0° C) (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-Attended Fever (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of Pain/Fever (1st vacc.) (N=100;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of Pain/Fever (1st vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local AEs (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic AEs (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;38.0° C) (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-Attended Fever (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of Pain/Fever (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of Pain/Fever (2nd vacc.) (N=99;55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (8 to 12 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.</title>
        <description>Number of subjects (8 to 12 years of age) reporting solicited local and systemic adverse events after receiving Bexsero® booster vaccine.</description>
        <time_frame>From day 1 (6 hr) through day 7 after vaccination</time_frame>
        <population>Analysis was done on solicited safety set: All subjects in the Exposed Set with solicited adverse event data.</population>
        <group_list>
          <group group_id="O1">
            <title>02_6_10_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (8 to 12 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.</title>
          <description>Number of subjects (8 to 12 years of age) reporting solicited local and systemic adverse events after receiving Bexsero® booster vaccine.</description>
          <population>Analysis was done on solicited safety set: All subjects in the Exposed Set with solicited adverse event data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local AEs (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic AEs (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;38.0° C) (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-Attended Fever (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of Pain and/or Fever (N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of Pain and/or Fever (N=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Newly Recruited naïve Subjects (Aged 8 to 12 Years of Age) Solicited Local and Systemic Adverse Events After Receiving Bexsero® Vaccine.</title>
        <description>The number newly recruited naïve subjects (aged 8 to12 years of age) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.</description>
        <time_frame>From day 1(6 hr) through day 7 after vaccination</time_frame>
        <population>Analysis was done on solicited safety set: All subjects in the Exposed Set with solicited adverse event data.</population>
        <group_list>
          <group group_id="O1">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Newly Recruited naïve Subjects (Aged 8 to 12 Years of Age) Solicited Local and Systemic Adverse Events After Receiving Bexsero® Vaccine.</title>
          <description>The number newly recruited naïve subjects (aged 8 to12 years of age) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.</description>
          <population>Analysis was done on solicited safety set: All subjects in the Exposed Set with solicited adverse event data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local AEs (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (1st vacc.) (N=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic AEs (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (1st vacc.) (N=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (1st vacc.) (N=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (1st vacc.) (N=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (1st vacc.) (N=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (1st vacc.) (N=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (1st vacc.) (N=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;38.0° C) (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-Attended Fever (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of Pain and/or Fever (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of Pain and/or Fever (1st vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local AEs (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic AEs (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;38.0° C) (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically-Attended Fever (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of Pain and/or Fever (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of Pain and/or Fever (2nd vacc.) (N=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination.</title>
        <description>The number of subjects reporting unsolicited adverse events after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) or two cach up schedule of Bexsero® vaccine is reported.</description>
        <time_frame>From day 1 through day 7 after any vaccination and throughout entire study period for all other AEs.</time_frame>
        <population>Analysis was done on unsolicited safety set: All subjects in the Exposed Set with unsolicited adverse event data.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3H5_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O3">
            <title>68_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O4">
            <title>02_2_5_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O5">
            <title>02_6_10_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O6">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O7">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination.</title>
          <description>The number of subjects reporting unsolicited adverse events after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) or two cach up schedule of Bexsero® vaccine is reported.</description>
          <population>Analysis was done on unsolicited safety set: All subjects in the Exposed Set with unsolicited adverse event data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="100"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly or Probably Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to Premature Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs), Medically Attended AEs and AEs Leading to Withdrawal for Entire Study Period.</title>
        <description>The number of subjects reporting unsolicited SAEs, medically attended AEs and AEs leading to withdrawal after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in the parent study) or two catch-up schedule of Bexsero® vaccine is reported.</description>
        <time_frame>Throughout the entire study period</time_frame>
        <population>Analysis was done on unsolicited safety set: All subjects in the Exposed Set with unsolicited adverse event data.</population>
        <group_list>
          <group group_id="O1">
            <title>2H3H511_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3H5_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O3">
            <title>68_11_V</title>
            <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O4">
            <title>02_2_5_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O5">
            <title>02_6_10_V</title>
            <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
          </group>
          <group group_id="O6">
            <title>NAIVE 123</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O7">
            <title>NAIVE_4A</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
          <group group_id="O8">
            <title>NAIVE_4B</title>
            <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs), Medically Attended AEs and AEs Leading to Withdrawal for Entire Study Period.</title>
          <description>The number of subjects reporting unsolicited SAEs, medically attended AEs and AEs leading to withdrawal after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in the parent study) or two catch-up schedule of Bexsero® vaccine is reported.</description>
          <population>Analysis was done on unsolicited safety set: All subjects in the Exposed Set with unsolicited adverse event data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="100"/>
                <count group_id="O7" value="55"/>
                <count group_id="O8" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly or probably related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited and unsolicited AEs were collected from Day 1 (30 minutes ) throughout Day 7; SAEs, medically-attended AEs and AEs leading to premature withdrawal were collected throughout the entire study period.</time_frame>
      <desc>Subjects in the 2H3H511_NV Group, 3H5_11_NV Group, 68_11_NV Group, 02_2_5_NV Group and 02_6_10_NV Group were only evaluated for antibody persistence and hence not included in the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>2H3H511_V</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="E2">
          <title>3H5_11_V</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="E3">
          <title>68_11_V</title>
          <description>In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="E4">
          <title>02_2_5_V</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="E5">
          <title>02_6_10_V</title>
          <description>In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.</description>
        </group>
        <group group_id="E6">
          <title>NAIVE 123</title>
          <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
        </group>
        <group group_id="E7">
          <title>NAIVE_4A</title>
          <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
        </group>
        <group group_id="E8">
          <title>NAIVE_4B</title>
          <description>Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="86" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="97" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="55" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="50" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="65" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="37" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="84" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="94" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="55" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="48" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="34" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="91"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

